AU2017382176A1 - Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof - Google Patents
Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof Download PDFInfo
- Publication number
- AU2017382176A1 AU2017382176A1 AU2017382176A AU2017382176A AU2017382176A1 AU 2017382176 A1 AU2017382176 A1 AU 2017382176A1 AU 2017382176 A AU2017382176 A AU 2017382176A AU 2017382176 A AU2017382176 A AU 2017382176A AU 2017382176 A1 AU2017382176 A1 AU 2017382176A1
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- compound
- alkyl
- group
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 Cc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2c(*)[s]1 Chemical compound Cc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2c(*)[s]1 0.000 description 8
- TYIZJXQTBIPAAL-LBPRGKRZSA-N C=C(c1c(C2)cc[s]1)N2[C@@H](CCCC(N1)=O)C1=C Chemical compound C=C(c1c(C2)cc[s]1)N2[C@@H](CCCC(N1)=O)C1=C TYIZJXQTBIPAAL-LBPRGKRZSA-N 0.000 description 1
- QQEUVALVLHWIFU-HYQBYDJKSA-N Cc(c(Cl)c1)ccc1NC(NCc1c(CCC([C@@H](CCCC(N2)=O)C2=O)C2=[U])c2c[s]1)=O Chemical compound Cc(c(Cl)c1)ccc1NC(NCc1c(CCC([C@@H](CCCC(N2)=O)C2=O)C2=[U])c2c[s]1)=O QQEUVALVLHWIFU-HYQBYDJKSA-N 0.000 description 1
- GYCALISHEPOBEI-ZDLGFXPLSA-N Cc(cc1)cc(C(F)(F)F)c1Oc(ccc(/C=C(/C(N1)=C)\SC1=O)c1)c1OC Chemical compound Cc(cc1)cc(C(F)(F)F)c1Oc(ccc(/C=C(/C(N1)=C)\SC1=O)c1)c1OC GYCALISHEPOBEI-ZDLGFXPLSA-N 0.000 description 1
- AKUUHZJELUGXBU-BAGZVPGASA-N Cc1c(CCC(CC[C@@H](CCCCN2)C2=O)C2=[U])c2c[s]1 Chemical compound Cc1c(CCC(CC[C@@H](CCCCN2)C2=O)C2=[U])c2c[s]1 AKUUHZJELUGXBU-BAGZVPGASA-N 0.000 description 1
- AENQQTFVQZABFQ-UHFFFAOYSA-M Cc1cccc(Nc2c(C)cnc(Nc(cc3)ccc3[O-])n2)c1 Chemical compound Cc1cccc(Nc2c(C)cnc(Nc(cc3)ccc3[O-])n2)c1 AENQQTFVQZABFQ-UHFFFAOYSA-M 0.000 description 1
- OPUFAOTZQPNEGH-BXWZNKKMSA-N O=C(CCC[C@@H]1CCC(CCc2c3[s]cc2C2CCCC2)C3=[U])NC1=O Chemical compound O=C(CCC[C@@H]1CCC(CCc2c3[s]cc2C2CCCC2)C3=[U])NC1=O OPUFAOTZQPNEGH-BXWZNKKMSA-N 0.000 description 1
- AJUJQOQCPJQFTQ-VIFPVBQESA-N O=C(c1c[s]cc1C1)N1[C@@H](CCCC(N1)=O)C1=O Chemical compound O=C(c1c[s]cc1C1)N1[C@@H](CCCC(N1)=O)C1=O AJUJQOQCPJQFTQ-VIFPVBQESA-N 0.000 description 1
- HXHZTWYUPMVYMN-PBJWXYPXSA-N [O-][N+](c([s]cc1C(C(C2)/C=C/[C@@H](CCCC(N3)=O)C3=O)=[U])c1C2=O)=O Chemical compound [O-][N+](c([s]cc1C(C(C2)/C=C/[C@@H](CCCC(N3)=O)C3=O)=[U])c1C2=O)=O HXHZTWYUPMVYMN-PBJWXYPXSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437400P | 2016-12-21 | 2016-12-21 | |
| US62/437,400 | 2016-12-21 | ||
| US201762485563P | 2017-04-14 | 2017-04-14 | |
| US62/485,563 | 2017-04-14 | ||
| US201762538203P | 2017-07-28 | 2017-07-28 | |
| US62/538,203 | 2017-07-28 | ||
| PCT/US2017/067353 WO2018118947A1 (en) | 2016-12-21 | 2017-12-19 | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017382176A1 true AU2017382176A1 (en) | 2019-05-30 |
Family
ID=60991575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017382176A Abandoned AU2017382176A1 (en) | 2016-12-21 | 2017-12-19 | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10040804B2 (enExample) |
| EP (1) | EP3559005A1 (enExample) |
| JP (1) | JP2020504711A (enExample) |
| KR (1) | KR20190093205A (enExample) |
| CN (1) | CN110099907A (enExample) |
| AU (1) | AU2017382176A1 (enExample) |
| CA (1) | CA3043938A1 (enExample) |
| IL (1) | IL267323A (enExample) |
| MX (1) | MX387646B (enExample) |
| RU (1) | RU2771166C2 (enExample) |
| TW (2) | TW201835089A (enExample) |
| WO (1) | WO2018118947A1 (enExample) |
| ZA (1) | ZA201903479B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| JP2020504711A (ja) | 2016-12-21 | 2020-02-13 | バイオセリックス， インコーポレイテッド | タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用 |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| US10584133B2 (en) * | 2018-03-30 | 2020-03-10 | Biotheryx, Inc. | Thienopyrimidinone compounds |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| US11191769B2 (en) * | 2018-06-13 | 2021-12-07 | Biotheryx, Inc. | Fused thiophene compounds |
| MX2021001957A (es) | 2018-08-22 | 2021-07-15 | Cullgen Shanghai Inc | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| WO2020160192A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020160193A2 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12559463B2 (en) | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
| FR3092581A1 (fr) * | 2019-02-12 | 2020-08-14 | Impact Biomedicines, Inc | Formes cristallines d'un inhibiteur de jak2 |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| CN114502543A (zh) * | 2019-05-24 | 2022-05-13 | 拜欧斯瑞克斯公司 | 靶向蛋白化合物、其药物组合物及治疗应用 |
| WO2021022163A2 (en) | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| TW202124374A (zh) * | 2019-09-13 | 2021-07-01 | 美商拜歐斯瑞克斯公司 | Ras蛋白降解劑、其醫藥組合物及其治療應用 |
| JP7629459B2 (ja) | 2019-11-19 | 2025-02-13 | ブリストル－マイヤーズ スクイブ カンパニー | Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物 |
| EP4681715A3 (en) | 2019-12-20 | 2026-01-28 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
| US12528825B2 (en) | 2020-01-29 | 2026-01-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| MX2022009308A (es) | 2020-01-29 | 2022-08-22 | Foghorn Therapeutics Inc | Compuestos y usos de estos. |
| BR112022016901A2 (pt) | 2020-02-26 | 2022-12-06 | Cullgen Shanghai Inc | Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso |
| CN119823124A (zh) | 2020-03-05 | 2025-04-15 | C4医药公司 | 用于brd9的靶向降解的化合物 |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| CN116490186B (zh) | 2020-08-05 | 2025-10-31 | C4医药公司 | 用于ret的靶向降解的化合物 |
| US20240025863A1 (en) | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022072538A1 (en) * | 2020-09-30 | 2022-04-07 | Biotheryx, Inc. | Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications |
| CN122562781A (zh) * | 2020-10-07 | 2026-08-14 | 上海睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
| TW202231269A (zh) | 2020-10-23 | 2022-08-16 | 美商拜歐斯瑞克斯公司 | Kras蛋白降解劑、其醫藥組合物及其治療應用 |
| US20240124418A1 (en) | 2020-12-14 | 2024-04-18 | Biotheryx, Inc. | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| PE20231941A1 (es) | 2021-04-06 | 2023-12-05 | Bristol Myers Squibb Co | Compuestos de oxoisoindolina sustituidos con piridinilo |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| AU2022290851A1 (en) | 2021-06-08 | 2023-11-23 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| US11767330B2 (en) | 2021-07-06 | 2023-09-26 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| US12662467B2 (en) | 2022-04-18 | 2026-06-23 | BioThery X, Inc. | Isoindolinones, pharmaceutical compositions, and therapeutic applications |
| EP4511128A1 (en) | 2022-04-20 | 2025-02-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| IL316803A (en) | 2022-06-06 | 2025-01-01 | C4 Therapeutics Inc | Bicyclic glutarimide-modified cervalon-binding agents |
| JP2025531869A (ja) * | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物 |
| WO2024096753A1 (en) | 2022-11-02 | 2024-05-10 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| EP4735451A1 (en) | 2023-06-30 | 2026-05-06 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| CN122228262A (zh) | 2023-11-02 | 2026-06-16 | 金橘生物科技公司 | 降解剂及其用途 |
| WO2025240386A1 (en) * | 2024-05-13 | 2025-11-20 | Saint Joseph's University | Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor |
| TW202617734A (zh) * | 2024-06-21 | 2026-05-01 | 大陸商杭州中美華東製藥有限公司 | Gspt1降解劑化合物、包含其的藥物組合物和用途 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5153192A (en) | 1990-04-09 | 1992-10-06 | Alcon Laboratories, Inc. | Thiophene sulfonamides useful as carbonic anhydrase inhibitors |
| US5378703A (en) | 1990-04-09 | 1995-01-03 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
| US5585377A (en) | 1990-04-09 | 1996-12-17 | Alcon Laboratories, Inc. | Sulfonamides useful as carbonic anhydrase inhibitors |
| DE4023048A1 (de) | 1990-07-20 | 1992-01-23 | Basf Ag | Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| ES2118941T3 (es) | 1992-02-21 | 1998-10-01 | Alcon Lab Inc | Composiciones antiglaucoma topicas que comprenden inhibidores de anhidrasa carbonica y bloqueantes beta. |
| US5420923A (en) | 1993-02-16 | 1995-05-30 | Scientific-Atlanta, Inc. | Addressed messaging in a cable television system |
| US5334596A (en) | 1993-05-11 | 1994-08-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| CA2188772A1 (en) | 1994-06-08 | 1995-12-14 | Balreddy Kamireddy | Cyclic sulfonamide herbicides |
| AU3619795A (en) | 1994-10-11 | 1996-05-02 | Takeda Chemical Industries Ltd. | Substituted heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors |
| TR199801665T2 (xx) | 1996-02-26 | 1998-12-21 | Advanced Research & Technology Institute | Makular �demin engellenmesi i�in karbonik anhidraz inhibit�rlerinin kullan�m�. |
| ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
| JPH10264532A (ja) | 1997-03-24 | 1998-10-06 | Fuji Photo Film Co Ltd | 感熱記録材料 |
| AU753020B2 (en) | 1998-04-30 | 2002-10-03 | Sumitomo Chemical Company, Limited | Method for giving resistance to weed control compounds to plants |
| US6906245B1 (en) | 1998-04-30 | 2005-06-14 | Sumitomo Chemical Company, Limited | Method for producing transgenic plants resistant to weed control compounds which disrupt the porphyrin pathways of plants |
| JP2000159761A (ja) | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | フルオロサリドマイド |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| JP4821036B2 (ja) | 1999-10-29 | 2011-11-24 | 住友化学株式会社 | 除草剤耐性植物 |
| JP4821038B2 (ja) | 1999-10-29 | 2011-11-24 | 住友化学株式会社 | 除草剤耐性植物 |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| DE10133665A1 (de) | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
| JP2004018434A (ja) | 2002-06-14 | 2004-01-22 | Mitsui Chemicals Inc | 新規なフッ素化イミド化合物、および該化合物を用いた電子写真感光体、電子写真装置、有機電界発光素子 |
| PT1578741E (pt) | 2002-12-23 | 2011-10-17 | 4Sc Ag | Compostos aromáticos como agentes antiinflamatórios, imunoreguladores e antiproliferativos |
| US7247736B2 (en) | 2002-12-23 | 2007-07-24 | 4Sc Ag | Method of identifying inhibitors of DHODH |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| CN100398534C (zh) | 2003-09-15 | 2008-07-02 | 天津和美生物技术有限公司 | 合成酞胺哌啶酮及其衍生物的方法 |
| SE0400970D0 (sv) | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| EP1817025A2 (en) | 2004-11-23 | 2007-08-15 | PTC Therapeutics, Inc. | Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| US8877780B2 (en) * | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| DK2061765T3 (en) | 2006-09-01 | 2015-01-26 | Senhwa Biosciences Inc | Serine-threonine protein kinase AND PARP-MODULATOR |
| WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
| CN101186611B (zh) | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用 |
| CN101186612B (zh) * | 2006-11-15 | 2012-10-03 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用 |
| EP1975165A1 (de) | 2007-03-27 | 2008-10-01 | Boehringer Ingelheim Pharma GmbH & Co. KG | Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel |
| JP2008273924A (ja) | 2007-03-30 | 2008-11-13 | Meiji Seika Kaisha Ltd | ２位チエニルカルバペネム誘導体 |
| KR101128943B1 (ko) | 2007-04-13 | 2012-03-27 | 주식회사 엘지화학 | 디옥시피롤기를 포함하는 헤테로고리 화합물 및 이를이용한 유기 전자 소자 |
| CN102245600A (zh) | 2008-10-08 | 2011-11-16 | 百时美施贵宝公司 | 吡咯烷酮黑色素浓集激素受体-1拮抗剂 |
| KR20110093841A (ko) | 2008-11-07 | 2011-08-18 | 4에스체 악티엔게젤샤프트 | 자가면역 질환의 치료를 위한 ｄｈｏｄｈ 억제제 및 메토트렉세이트를 포함하는 조합 요법 |
| CA2756989A1 (en) | 2009-04-03 | 2010-10-07 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| ES2537190T3 (es) | 2010-09-01 | 2015-06-03 | Gilead Connecticut, Inc. | Piridazinonas, procedimiento de preparación y procedimientos de utilización de las mismas |
| US20120085992A1 (en) | 2010-09-30 | 2012-04-12 | The Regents Of The University Of California | Furan Conjugated Polymers Useful for Photovoltaic Applications |
| WO2012082893A2 (en) | 2010-12-15 | 2012-06-21 | Plextronics, Inc. | Fluoro monomers, oligomers, and polymers for inks and organic electronic devices |
| JP2014517820A (ja) | 2011-04-15 | 2014-07-24 | ジョージア テック リサーチ コーポレーション | ナフタレンジイミドのスタンニル誘導体及び関連組成物並びに方法 |
| ITMI20110881A1 (it) | 2011-05-18 | 2012-11-19 | E T C Srl | Materiale semiconduttore organico |
| WO2013052153A1 (en) | 2011-10-05 | 2013-04-11 | Georgia Tech Research Corporation | Blends of organic semiconductor compounds and electrically insulating amorphous polymers, methods and devices |
| JP2014047192A (ja) | 2012-09-03 | 2014-03-17 | Sumitomo Chemical Co Ltd | 化合物、並びに、該化合物を含有する有機半導体材料、有機半導体素子 |
| JP2014047196A (ja) | 2012-09-03 | 2014-03-17 | Sumitomo Chemical Co Ltd | 化合物及び高分子化合物、並びに、該化合物又は該高分子化合物を含有する有機半導体材料及び該有機半導体材料を用いた有機半導体素子 |
| CN103664916B (zh) | 2012-09-12 | 2016-08-24 | 中国科学院化学研究所 | 基于联噻吩亚二吡咯及其衍生物的共轭小分子材料及其制备方法与应用 |
| ITMI20121691A1 (it) | 2012-10-09 | 2014-04-10 | E T C Srl | Materiale semiconduttore organico |
| ITMI20121939A1 (it) | 2012-11-15 | 2014-05-16 | E T C Srl | Materiale organico semiconduttore |
| ITMI20121952A1 (it) | 2012-11-16 | 2014-05-17 | E T C Srl | Materiale semiconduttore organico |
| WO2014089324A1 (en) | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
| JP2014185147A (ja) | 2013-02-22 | 2014-10-02 | Mitsubishi Chemicals Corp | イミド縮合環化合物及びイミド縮合環化合物の製造方法 |
| JP6248400B2 (ja) | 2013-03-15 | 2017-12-20 | 株式会社リコー | 感光体及び画像形成装置 |
| JP2015013989A (ja) | 2013-06-05 | 2015-01-22 | 三菱化学株式会社 | コポリマー、半導体層形成用組成物、有機電子デバイス及び太陽電池モジュール |
| WO2014204082A1 (ko) | 2013-06-20 | 2014-12-24 | 경상대학교산학협력단 | 유기 반도체 화합물, 이의 제조방법 및 이를 채용한 유기 태양전지 |
| KR101595919B1 (ko) | 2013-08-30 | 2016-02-29 | 한국과학기술연구원 | 전도성 유기 반도체 화합물 및 이를 포함하는 유기태양전지 |
| US9809594B2 (en) | 2013-09-10 | 2017-11-07 | University Of Washington Through Its Center For Commercialization | Non-fullerene electron acceptors for organic photovoltaic devices |
| KR101732220B1 (ko) | 2014-03-31 | 2017-05-02 | 주식회사 엘지화학 | 헤테로환 화합물 및 이를 포함하는 유기 태양 전지 |
| CN105294536B (zh) | 2014-06-30 | 2018-06-29 | 中国科学院上海有机化学研究所 | 一种制备3-亚氨基异吲哚啉酮类化合物的方法 |
| AU2015305449B2 (en) * | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| CN104230953B (zh) | 2014-08-25 | 2016-08-17 | 中国科学院上海有机化学研究所 | 含2-(1,3-二硫/硒-2-亚基)乙氰共轭结构单元的萘二酰亚胺及其衍生物 |
| WO2016061751A1 (en) | 2014-10-22 | 2016-04-28 | Merck Sharp & Dohme Corp. | Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors |
| CN105693745B (zh) | 2014-11-27 | 2019-07-05 | 中国科学院苏州纳米技术与纳米仿生研究所 | 有机π-共轭化合物、其制备方法及应用 |
| AU2016266942B2 (en) | 2015-05-22 | 2018-10-18 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| JP2020504711A (ja) | 2016-12-21 | 2020-02-13 | バイオセリックス， インコーポレイテッド | タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用 |
-
2017
- 2017-12-19 JP JP2019526486A patent/JP2020504711A/ja active Pending
- 2017-12-19 MX MX2019007434A patent/MX387646B/es unknown
- 2017-12-19 AU AU2017382176A patent/AU2017382176A1/en not_active Abandoned
- 2017-12-19 WO PCT/US2017/067353 patent/WO2018118947A1/en not_active Ceased
- 2017-12-19 RU RU2019115392A patent/RU2771166C2/ru active
- 2017-12-19 KR KR1020197018882A patent/KR20190093205A/ko not_active Ceased
- 2017-12-19 CA CA3043938A patent/CA3043938A1/en not_active Abandoned
- 2017-12-19 CN CN201780079826.3A patent/CN110099907A/zh active Pending
- 2017-12-19 US US15/847,628 patent/US10040804B2/en active Active
- 2017-12-19 EP EP17829823.8A patent/EP3559005A1/en not_active Withdrawn
- 2017-12-21 TW TW106145115A patent/TW201835089A/zh unknown
- 2017-12-21 TW TW109142439A patent/TWI756957B/zh not_active IP Right Cessation
-
2018
- 2018-06-18 US US16/011,090 patent/US10336771B2/en active Active
-
2019
- 2019-05-30 ZA ZA2019/03479A patent/ZA201903479B/en unknown
- 2019-06-13 IL IL267323A patent/IL267323A/en unknown
- 2019-06-28 US US16/457,409 patent/US10889593B2/en active Active
-
2021
- 2021-01-11 US US17/146,479 patent/US11345714B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110099907A (zh) | 2019-08-06 |
| MX387646B (es) | 2025-03-18 |
| US20180298027A1 (en) | 2018-10-18 |
| ZA201903479B (en) | 2021-09-29 |
| IL267323A (en) | 2019-08-29 |
| RU2771166C2 (ru) | 2022-04-27 |
| US10336771B2 (en) | 2019-07-02 |
| RU2019115392A (ru) | 2021-01-22 |
| MX2019007434A (es) | 2019-08-16 |
| TW202120514A (zh) | 2021-06-01 |
| US20190322683A1 (en) | 2019-10-24 |
| JP2020504711A (ja) | 2020-02-13 |
| US10040804B2 (en) | 2018-08-07 |
| CA3043938A1 (en) | 2018-06-28 |
| TW201835089A (zh) | 2018-10-01 |
| WO2018118947A1 (en) | 2018-06-28 |
| TWI756957B (zh) | 2022-03-01 |
| US20210139500A1 (en) | 2021-05-13 |
| US20180170948A1 (en) | 2018-06-21 |
| US10889593B2 (en) | 2021-01-12 |
| EP3559005A1 (en) | 2019-10-30 |
| KR20190093205A (ko) | 2019-08-08 |
| US11345714B2 (en) | 2022-05-31 |
| RU2019115392A3 (enExample) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11345714B2 (en) | Compounds targeting proteins, compositions, methods, and uses thereof | |
| US10857155B2 (en) | Compounds targeting proteins, compositions, methods, and uses thereof | |
| US10562917B2 (en) | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | |
| US10905684B2 (en) | Aminoamide compounds | |
| JP7009466B2 (ja) | アンドロゲン受容体の標的分解のための化合物および方法 | |
| EP3807283A1 (en) | Fused thiophene compounds | |
| CN113423701A (zh) | 取代的异吲哚啉酮 | |
| CN108137507A (zh) | 基于mdm2的蛋白水解调节剂和相关的使用方法 | |
| WO2019173224A1 (en) | Deuterated compounds and chimeras and uses thereof | |
| CA3094988A1 (en) | Thienopyrimidinone compounds | |
| CA3042693A1 (en) | Pyrrole amides as .alpha.v integrin inhibitors | |
| CN120441548A (zh) | Cereblon结合化合物、其组合物及其用于治疗的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |